Julie Hallet1,2,3,4, Laura E Davis5, Alyson L Mahar6, Ying Liu7, Victoria Zuk5, Vaibhav Gupta8, Craig C Earle7,9, Natalie G Coburn10,8,5,7. 1. Division of Surgical Oncology, Odette Cancer Centre-Sunnybrook Health Sciences Centre, 2075 Bayview avenue, T2-063, Toronto, ON, M4N 3M5, Canada. Julie.hallet@sunnybrook.ca. 2. Department of Surgery, University of Toronto, Toronto, ON, Canada. Julie.hallet@sunnybrook.ca. 3. Sunnybrook Research Institute, Toronto, ON, Canada. Julie.hallet@sunnybrook.ca. 4. ICES, Toronto, ON, Canada. Julie.hallet@sunnybrook.ca. 5. Sunnybrook Research Institute, Toronto, ON, Canada. 6. Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 7. ICES, Toronto, ON, Canada. 8. Department of Surgery, University of Toronto, Toronto, ON, Canada. 9. Division of Medical Oncology, Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 10. Division of Surgical Oncology, Odette Cancer Centre-Sunnybrook Health Sciences Centre, 2075 Bayview avenue, T2-063, Toronto, ON, M4N 3M5, Canada.
Abstract
BACKGROUND: While surgical care by high-volume providers for esophago-gastric cancer (EGC) yields better outcomes, volume-outcome relationships are unknown for systemic therapy. We examined receipt of therapy and outcomes in the non-curative management of EGC based on medical oncology provider volume. METHODS: We conducted a population based retrospective cohort study of non-curative EGC over 2005-2017 by linking administrative healthcare datasets. The volume of new EGC consultations per medical oncology provider per year was calculated and divided into quintiles. High-volume (HV) medical oncologists were defined as the 4-5th quintiles. Outcomes were receipt of chemotherapy and overall survival (OS). Multivariate logistic and Cox-proportional hazards regressions examined the association between management by HV medical oncologist, receipt of systemic therapy, and OS. RESULTS: 7011 EGC patients with non-curative management consulted with medical oncology. 1-year OS was superior for HV medical oncologists (> 11 patients/year), with 28.4% (95% CI 26.7-30.2%) compared to 25.1% (95% CI 23.8-26.3%) for low volume (p < 0.001). After adjusting for age, sex, comorbidity burden, rurality, income quintile, and diagnosis year, HV medical oncologist was independently associated with higher odds of receiving chemotherapy (OR 1.13, 95% CI 1.01-1.26), and independently associated with superior OS (HR 0.89, 95% CI 0.84-0.93). CONCLUSIONS: Medical oncology provider volume was associated with variation in non-curative management and outcomes of EGC. Care by an HV medical oncologist was independently associated with higher odds of receiving chemotherapy and superior OS, after adjusting for case mix. This information is important to inform disease care pathways and care organization; an increase in the number of HV medical oncologists may reduce variation and improve outcomes.
BACKGROUND: While surgical care by high-volume providers for esophago-gastric cancer (EGC) yields better outcomes, volume-outcome relationships are unknown for systemic therapy. We examined receipt of therapy and outcomes in the non-curative management of EGC based on medical oncology provider volume. METHODS: We conducted a population based retrospective cohort study of non-curative EGC over 2005-2017 by linking administrative healthcare datasets. The volume of new EGC consultations per medical oncology provider per year was calculated and divided into quintiles. High-volume (HV) medical oncologists were defined as the 4-5th quintiles. Outcomes were receipt of chemotherapy and overall survival (OS). Multivariate logistic and Cox-proportional hazards regressions examined the association between management by HV medical oncologist, receipt of systemic therapy, and OS. RESULTS: 7011 EGCpatients with non-curative management consulted with medical oncology. 1-year OS was superior for HV medical oncologists (> 11 patients/year), with 28.4% (95% CI 26.7-30.2%) compared to 25.1% (95% CI 23.8-26.3%) for low volume (p < 0.001). After adjusting for age, sex, comorbidity burden, rurality, income quintile, and diagnosis year, HV medical oncologist was independently associated with higher odds of receiving chemotherapy (OR 1.13, 95% CI 1.01-1.26), and independently associated with superior OS (HR 0.89, 95% CI 0.84-0.93). CONCLUSIONS: Medical oncology provider volume was associated with variation in non-curative management and outcomes of EGC. Care by an HV medical oncologist was independently associated with higher odds of receiving chemotherapy and superior OS, after adjusting for case mix. This information is important to inform disease care pathways and care organization; an increase in the number of HV medical oncologists may reduce variation and improve outcomes.
Authors: Daniel J Kagedan; Liza Abraham; Nik Goyert; Qing Li; Lawrence F Paszat; Alexander Kiss; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: Cancer Date: 2016-07-08 Impact factor: 6.860
Authors: Tait D Shanafelt; Neil E Kay; Kari G Rabe; David J Inwards; Clive S Zent; Jose F Leis; Susan M Schwager; Carrie A Thompson; Deborah A Bowen; Thomas E Witzig; Susan L Slager; Timothy G Call Journal: Cancer Date: 2011-08-26 Impact factor: 6.860
Authors: Scott R Berry; Chaim M Bell; Peter A Ubel; William K Evans; Eric Nadler; Elizabeth L Strevel; Peter J Neumann Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: John D Birkmeyer; Therese A Stukel; Andrea E Siewers; Philip P Goodney; David E Wennberg; F Lee Lucas Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Catherine Ireland; Eric Wiedower; Muhammad Mirza; Melissa Crawley; Alexandria Tran; George Yaghmour; Mike G Martin Journal: World J Oncol Date: 2018-05-01
Authors: Julie Hallet; Nicole J Look Hong; Victoria Zuk; Laura E Davis; Vaibhav Gupta; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: Gastric Cancer Date: 2019-12-13 Impact factor: 7.370
Authors: Elliott K Yee; Natalie G Coburn; Victoria Zuk; Laura E Davis; Alyson L Mahar; Ying Liu; Vaibhav Gupta; Gail Darling; Julie Hallet Journal: Gastric Cancer Date: 2021-02-06 Impact factor: 7.370